Login Register Cart 0
Generic placeholder image

Recent Advances in Drug Delivery and Formulation

Editor-in-Chief

ISSN (Print): 2667-3878
ISSN (Online): 2667-3886

Back
Journal Home About Journal Editorial Board Current Issue Volumes/Issues
Subscribe
Research Article

Development of Bromfenac Sodium Loaded Pluronic Nanomicelles: Characterization and Corneal Permeation Study

Author(s): Miral Patel, Nithun Saha, Shruti Patel, Priyanka Ahlawat, Abhay Dharamsi and Asha Patel*

Volume 16, Issue 1, 2022

Published on: 02 March, 2022

Page: [68 - 78] Pages: 11

DOI: 10.2174/2667387816666220128123737

Price: $65

Abstract

Background: The Cataract is the leading cause of visual impairment and preventable blindness worldwide. Cataract removal surgery involves various post-operative complications like pain and inflammation.

Objectives: The objective of this study is to screen the polymer concentration as well as optimize the formulation components to develop the pluronic micelles with nanosized characterization and for enhanced corneal permeation study.

Methodology: For optimization, Central Composite design was employed to study the effect of independent variables, concentration of Pluronic F 127 (X1) and the concentration of Hyaluronic acid (X2) on chosen responses (Y 1 ) Micelle size, (Y 2 ) Entrapment Efficiency, (Y 3 ) Viscosity. The lyophilised powder was used for physical characterisation.

Results: The formulation containing 5%w/v Pluronic F127 and 0.2%w/v Hyaluronic acid was the optimised composition with micelle size and zeta potential 38.74±4.12nm and -17.6±0.1 mV respectively. In-vitro drug release was found to be 91.72±1.2 percentage in 8 hours. Surface morphology revealed micelles were spherical in shape. Ocular irritancy study showed that formulation was safe and non-irritant. In vitro corneal permeation studies through excised rabbit cornea indicated 1.5 fold increase in ocular availability without corneal damage compared to an aqueous suspension containing the same amount of drug in nanomicelles.

Conclusion: In a nutshell, Pluronic Nanomicelles would be a platform for the delivery of Bromfenac Sodium.

Keywords: Bromfenac sodium, hyaluronic acid, pluronic micelles, lyophilisation, corneal permeation study.

« Previous Next »
Graphical Abstract

[1]
Rajpal RK, Ross B, Rajpal SD, Hoang K. Bromfenac ophthalmic solution for the treatment of postoperative ocular pain and inflammation: Safety, efficacy, and patient adherence. Patient Prefer Adherence 2014; 8: 925-31.
[http://dx.doi.org/10.2147/PPA.S46667] [PMID: 25028541]
[2]
Cho H, Wolf KJ, Wolf EJ. Management of ocular inflammation and pain following cataract surgery: Focus on bromfenac ophthalmic solution. Clin Ophthalmol 2009; 3: 199-210.
[http://dx.doi.org/10.2147/OPTH.S4806] [PMID: 19668566]
[3]
Ghlichloo I, Gerriets V. Nonsteroidal Anti-inflammatory Drugs (NSAIDs). Available from: https://www.ncbi.nlm.nih.gov/books/NBK547742/ (Accessed on May 12, 2021).
[4]
Yanni JM, Graff G, Hellberg MR. Topically administrable compositions containing 3-benzoylphenylacetic acid derivatives for treatment of ophthalmic inflammatory disorders. Fort Worth, TX: Alcon Laboratories, Inc U.S. Patent 5475034, 1995.
[5]
Waterbury LD, Silliman D, Jolas T. Comparison of cyclooxygenase inhibitory activity and ocular anti-inflammatory effects of ketorolac tromethamine and bromfenac sodium. Curr Med Res Opin 2006; 22(6): 1133-40.
[http://dx.doi.org/10.1185/030079906X112471] [PMID: 16846546]
[6]
Ogawa T, Sakaue T, Terai T, Fukiage C. Effects of bromfenac sodium, non-steroidal anti-inflammatory drug, on acute ocular inflammation. Nippon Ganka Gakkai Zasshi 1995; 99(4): 406-11.
[PMID: 7741052]
[7]
Jung YS, Park W, Park H, Lee DK, Na K. Thermo-sensitive injectable hydrogel based on the physical mixing of hyaluronic acid and Pluronic F-127 for sustained NSAID delivery. Carbohydr Polym 2017; 156: 403-8.
[http://dx.doi.org/10.1016/j.carbpol.2016.08.068] [PMID: 27842839]
[8]
Suksiriworapong J, Rungvimolsin T. A-gomol A, Junyaprasert VB, Chantasart D. Development and characterization of lyophilized diazepam-loaded polymeric micelles. AAPS PharmSciTech 2014; 15(1): 52-64.
[http://dx.doi.org/10.1208/s12249-013-0032-4] [PMID: 24092522]
[9]
Gonzalez-Mira E, Egea MA, Souto EB, Calpena AC, García ML. Optimizing flurbiprofen-loaded NLC by central composite factorial design for ocular delivery. Nanotechnology 2011; 22(4)045101
[http://dx.doi.org/10.1088/0957-4484/22/4/045101] [PMID: 21169662]
[10]
Qi H, Li L, Huang C, Li W, Wu C. Optimization and physicochemical characterization of thermosensitive poloxamer gel containing puerarin for ophthalmic use. Chem Pharm Bull (Tokyo) 2006; 54(11): 1500-7.
[http://dx.doi.org/10.1248/cpb.54.1500] [PMID: 17077546]
[11]
Gupta AK, Madan S, Majumdar DK, Maitra A. Ketorolac entrapped in polymeric micelles: Preparation, characterisation and ocular anti-inflammatory studies. Int J Pharm 2000; 209(1-2): 1-14.
[http://dx.doi.org/10.1016/S0378-5173(00)00508-1] [PMID: 11084241]
[12]
Abdelrahman A, Salem H, Khallaf R, Ali A. Modeling, optimization, and in vitro corneal permeation of chitosan-lomefloxacin HCl nanosuspension intended for ophthalmic delivery. J Pharm Innov 2015; 10: 254-68.
[http://dx.doi.org/10.1007/s12247-015-9224-7]
[13]
Butt AM, Mohd Amin MC, Katas H. Synergistic effect of pH-responsive folate-functionalized poloxamer 407-TPGS-mixed micelles on targeted delivery of anticancer drugs. Int J Nanomedicine 2015; 10(1): 1321-34.
[PMID: 25709451]
[14]
Butt A, Amin M, Katas H, Sarisuta N, Witoonsaridsilp W, Benjakul R. In vitro characterization of pluronic F127 and D-tocopheryl polyethylene glycol 1000 succinate mixed micelles as nanocarriers for targeted anticancer-drug delivery. J Nanomater 2012; 2012: 1-11.
[http://dx.doi.org/10.1155/2012/916573]
[15]
Makwana SB, Patel VA, Parmar SJ. Development and characterization of in-situ gel for ophthalmic formulation containing ciprofloxacin hydrochloride. Results Pharma Sci 2015; 6: 1-6.
[http://dx.doi.org/10.1016/j.rinphs.2015.06.001] [PMID: 26949596]
[16]
U.S. pharmacopoeia- national formulary [USP 36–NF 31].2013; 791: 354-5.
[17]
U.S. pharmacopoeia- national formulary [USP 36–NF 31].2013; 785.
[18]
Vengurlekar P, Singh S, Rathod S. Microspheric in-situ gel for ocular drug delivery system of bromfenac sodium. Int J Pharm Sci Res 2014; 5: 179-85.
[19]
Keservani RK, Sharma AK. Nanodispersions for drug delivery. CRC Press Taylor & Francis Group 2012; 55: 427-8.
[20]
Darwhekar G, Jain P, Jain D, Agrawal G. Development and optimization of dorzolamide hydrochloride and timolol maleate in situ gel for glaucoma treatment. Asian J Pharm Ana 2011; 1: 93-7.
[21]
Bonferoni MC, Chetoni P, Giunchedi P, et al. Carrageenan-gelatin mucoadhesive systems for ion-exchange based ophthalmic delivery: In vitro and preliminary in vivo studies. Eur J Pharm Biopharm 2004; 57(3): 465-72.
[http://dx.doi.org/10.1016/j.ejpb.2003.12.002] [PMID: 15093594]
[22]
Steichen SD, Caldorera-Moore M, Peppas NA. A review of current nanoparticle and targeting moieties for the delivery of cancer therapeutics. Eur J Pharm Sci 2013; 48(3): 416-27.
[http://dx.doi.org/10.1016/j.ejps.2012.12.006] [PMID: 23262059]
[23]
Patel A, Cholkar K, Agrahari V, Mitra AK. Ocular drug delivery systems: An overview. World J Pharmacol 2013; 2(2): 47-64.
[http://dx.doi.org/10.5497/wjp.v2.i2.47] [PMID: 25590022]
[24]
Kumar S, Debjit B, Shravan P, Shweta S. Recent challenges and advances in ophthalmic drug delivery system. Pharma Innova J 2012; 4(1): 1-15.
[25]
Ahmed V, Goli D. Development and characterization of in situ gel of xanthan gum for ophthalmic formulation containing brimonidine tartrate. Asian J Pharm Clin Res 2018; 11: 277.
[http://dx.doi.org/10.22159/ajpcr.2018.v11i7.25221]

Rights & Permissions Print Cite
Article Metrics
42
1
© 2024 Bentham Science Publishers | Privacy Policy